Ken Griffin Greenwich Life Sciences, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 20,942 shares of GLSI stock, worth $175,493. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,942
Previous 13,768
52.11%
Holding current value
$175,493
Previous $124,000
64.52%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding GLSI
# of Institutions
49Shares Held
1.14MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY309KShares$2.59 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA282KShares$2.36 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA142KShares$1.19 Million0.0% of portfolio
-
State Street Corp Boston, MA81.9KShares$686,7070.0% of portfolio
-
Northern Trust Corp Chicago, IL75.9KShares$636,0830.0% of portfolio
About Greenwich LifeSciences, Inc.
- Ticker GLSI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,848,200
- Market Cap $108M
- Description
- Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...